Immunotherapy research primarily focuses on improving the body’s immune system’s recognition of cancer cells. However, ...

We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...

Simply put, BCR-ABL1 is an oncogene, a mutated gene that can cause cancer ... BCR-ABL1 is mainly associated with chronic myeloid leukemia (CML). In fact, an estimated 90% to 95% of people with ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License ...

Strengthening U.S. Biodefense. ATLANTA, GA - March 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in developing vaccines and immunotherapi ...

Surge Copper Corp. ("Surge" or the "Company") announces the grant of equity-based incentive awards under its Share Compensation Plan. The Company has awarded 4,583,334 restricted share units (RSUs) to ...

Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it ...

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

Researchers sought to determine whether zanubrutinib is more beneficial than ibrutinib in patients with CLL/SLL.

The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a ...